# OnCo record paper-krystal-1-crc-yaeger-nejm-2023 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-krystal-1-crc-yaeger-nejm-2023/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-krystal-1-crc-yaeger-nejm-2023" ;
  schema:name "KRYSTAL-1: adagrasib with or without cetuximab in KRAS G12C-mutated colorectal cancer"@en ;
  schema:description "The KRAS G12C inhibitor adagrasib on its own shrank about one in five previously treated colorectal cancers, but combined with the EGFR antibody cetuximab the response rate rose to nearly half, showing the two drugs are needed together in this disease."@en ;
  schema:url <https://onco.cc/key-papers/paper-krystal-1-crc-yaeger-nejm-2023/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa2212419>, <https://pubmed.ncbi.nlm.nih.gov/36546659/> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa2212419> ;
  schema:datePublished "2023"^^xsd:gYear ;
  schema:author "Yaeger R, Weiss J, Pelster MS, et al." ;
  onco:cancers <https://onco.cc/cancers/kras-g12c-colorectal/> ;
  onco:drugs <https://onco.cc/drugs/adagrasib/>, <https://onco.cc/drugs/cetuximab/> ;
  onco:journals <https://onco.cc/journals/nejm/> .